Skip to content

Effects of Low-level Mechanical Vibration on Bone Density in Ambulant Children Affected by Duchenne Muscular Dystrophy

Low-level Mechanical Vibration, Bone Density, Bone Resorption and Muscular Strength in Ambulant Children Affected by Duchenne Muscular Dystrophy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05281120
Enrollment
20
Registered
2022-03-16
Start date
2006-11-30
Completion date
2007-11-30
Last updated
2022-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne Muscular Dystrophy, Osteoporosis

Keywords

Duchenne Muscular Dystrophy, children, low bone mass, osteoporosis, low-level mechanical vibration, bone turnover markers

Brief summary

Duchenne muscular dystrophy (DMD) is a X-linked recessive disorder due to a mutation of the dystrophin gene (Xp21). Dystrophin is a sarcolemmal protein of skeletal and cardiac muscle, and its absence causes progressive muscle degeneration and substitution with fat and connective tissue. The progressive muscle degeneration leads to loss of autonomous walking before the age of 15 years and death for cardiac and/or respiratory failure. There are no specific treatment for DMD, and the standard of care is now based on long-term corticosteroid (CS) use. The studies on bone mass in DMD are very few, but they agree in reporting the presence of a reduced bone mass and an increased rate of fractures probably due to long-term steroid therapy and disuse-osteopenia. The aim of this study, involving 20 ambulant DMD boys (age 7-10 years) has been the evaluation of the effects of low-level mechanical vibrations on bone in a group of ambulant DMD children for 1 year, with RDA-adjusted dietary calcium intake and 25OH vitamin D supplementation.

Detailed description

All children were instructed to have a daily intake of calcium equal to the 100% of the RDA and were supplemented with calcifediol (0.7 mcg/kg/die). The 20 boys were randomly assigned to two groups: group 1 (mechanical intervention group) = a mechanical device (a small platform designed to induce vertical, sinusoidal acceleration) was installed in the home of each boy of group 1. group 2 (placebo control group) = a placebo device was installed in the home of each boy of group 2 All boys were instructed to stand on the platform for 10 minutes each day for 12 months. Compliance was followed and stimulated through weekly telephone contacts with parents and children.

Interventions

DEVICELow-level mechanical vibrations WITH vertical sinusoidal acceleration

Small platform designed to induce vertical, sinusoidal acceleration.

DEVICELow-level mechanical vibrations WITHOUT vertical sinusoidal acceleration

Small platform designed to NOT induce vertical, sinusoidal acceleration

Sponsors

Istituto Auxologico Italiano
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
7 Years to 10 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of DMD * Ability to stand up and walk (some balance assistance allowed, but full weight-bearing necessary) * All the children must already be on glucocorticoid therapy for at least 6 months before the start of the study.

Exclusion criteria

* Presence of other diseases interfering with bone density and bone turnover * The inability to regularly use the vibratory platform.

Design outcomes

Primary

MeasureTime frameDescription
Change in bone mineral density at lumbar spine.baseline and 12th monthBone mineral density evaluated by DXA. Bone mineral apparent density calculated to correct for bone size (growing subjects). Z-score calculated. Measurements: baseline and 12 months.

Secondary

MeasureTime frameDescription
Phosphatebaseline and 12th monthchanges in serum phosphate (mg/dL)
Magnesiumbaseline and 12th monthchanges in serum magnesium (mg/dL)
Creatininebaseline and 12th monthchanges in serum creatinine (mg/dL)
Bone Alkaline Phosphatasebaseline and 12th monthchanges in serum bone alkaline phosphatase (µg/L)
Calciumbaseline and 12th monthchanges in serum calcium (mg/dL)
Parathyroid Hormonebaseline and 12th monthchanges in serum parathyroid hormone (ng/L)
25-OH vitamin Dbaseline and 12th monthchanges in serum 25-OH vitamin D (µg/L)
1,25(OH)2 vitamin Dbaseline and 12th monthchanges in serum 1,25(OH)2 vitamin D (ng/L)
Osteocalcinbaseline and 12th monthchanges in serum osteocalcin (µg/L)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026